Neurofeedback for Mild Cognitive Impairment
Trial Summary
What is the purpose of this trial?
Mild cognitive impairment (MCI) has been identified as an early phase of Alzheimer's disease (AD), a neurodegenerative disorder expected to affect 13.9 million Americans by 2060. AD causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality. Treatment intervention at the MCI stage of the disease could potentially slow down the rate at which people may convert from MCI to AD. Increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in AD. Furthermore, previous research has shown that neurofeedback (NFB) training targeting these regions can improve memory, making it a potential treatment for AD. NFB is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor. We are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with MCI. Results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with MCI.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications likely to affect cognitive function, such as donepezil and memantine. Other medications are not excluded, but their effects will be examined during the study.
What data supports the effectiveness of the treatment Neurofeedback for Mild Cognitive Impairment?
Research shows that neurofeedback, a type of biofeedback that uses real-time brain activity to improve brain function, has been effective in enhancing cognitive functions like memory and attention in both healthy and older adults. Studies have demonstrated improvements in working memory and attention, suggesting potential benefits for those with mild cognitive impairment.12345
Is neurofeedback safe for humans?
How does the treatment Neurofeedback differ from other treatments for Mild Cognitive Impairment?
Neurofeedback is unique because it uses real-time brain activity monitoring to train the brain, aiming to improve memory and attention in people with Mild Cognitive Impairment. Unlike traditional treatments, it is non-invasive and involves training sessions that help enhance brain function by modulating brain waves, which has shown promising results in improving cognitive abilities.12101112
Eligibility Criteria
This trial is for individuals living independently with mild cognitive impairment (MCI), who can read English and consent to participate. It's not suitable for those with frontal temporal dementia, brain cancer, or recent stroke; people taking certain cognitive-affecting drugs like donepezil; or those with a history of significant head injury, seizures, or active substance abuse within the last year.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive gamma-neurofeedback (G-NFB) or placebo-NFB during 30-45 minute sessions twice per week for 12 weeks
Follow-up
Participants are monitored for durability of gamma band response and working memory accuracy after treatment
Treatment Details
Interventions
- Neurofeedback
Neurofeedback is already approved in United States, European Union, Canada for the following indications:
- Chronic low back pain
- Fibromyalgia
- Neuropathic pain
- Chronic pain
- Fibromyalgia
- Neuropathic pain
- Chronic pain
- Fibromyalgia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor